Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in:

Open Access 12-02-2025 | Hyperglycemia | Review

Screening and management of hospital hyperglycemia in non-critical patients: a position statement from the Brazilian Diabetes Society (SBD)

Authors: Emerson Cestari Marino, Denise Momesso, Marcos Tadashi Kakitani Toyoshima, Maria Fernanda Ozorio de Almeida, Beatriz D. Schaan, Leandra Anália Freitas Negretto, Augusto Cezar Santomauro Junior, Priscilla Cukier, Paulo Roberto Rizzo Genestreti, Alina Coutinho Rodrigues Feitosa, Jorge Eduardo da Silva Soares Pinto, Rogerio Silicani Ribeiro, Rodrigo Nunes Lamounier, Ruy Lyra, Marcello Casaccia Bertoluci

Published in: Diabetology & Metabolic Syndrome | Issue 1/2025

Login to get access

Abstract

Background

Hospital Hyperglycemia (HH) is linked to poorer outcomes, including higher mortality rates, increased ICU admissions, and extended hospital stays, and occurs in both people living with diabetes or not. The prevalence of HH in non-critical patients ranges from 22 to 46%. This panel reviewed the evidence and made recommendations for the best care for hospitalized hyperglycemic patients, with or without diabetes mellitus.

Methods

The methodology was published previously and was defined by the internal institutional steering committee. The SBD Acute and Hospital Complications Department drafted the manuscript, selecting key clinical questions for a narrative review using MEDLINE via PubMed. The best available evidence was reviewed, including randomized clinical trials (RCTs), meta-analyses, and high-quality observational studies related to Hospital Hyperglycemia.

Results and conclusions

The department members and external experts developed 23 recommendations for the management of patients with HH, including screening, initial interventions, treatment adjustments, and care for potential complications. Based on the best available evidence, our article provides safe and effective management strategies for both public and private healthcare settings.
Literature
1.
Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6.PubMedCrossRef
2.
Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–61.PubMedPubMedCentralCrossRef
3.
Christensen MB, Gotfredsen A, Nørgaard K. Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2017;33(5).
4.
Murad MH, Coburn JA, Coto-Yglesias F, Dzyubak S, Hazem A, Lane MA, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(1):49–58.PubMedCrossRef
5.
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810–5.PubMedCrossRef
6.
Bhatti JM, Raza SA, Shahid MO, Akhtar A, Ahmed T, Das B. Association between glycemic control and the outcome in hospitalized patients with COVID-19. Endocrine. 2022;77(2):213–20.PubMedPubMedCentralCrossRef
7.
van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan G-O, Dunson DB. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care. 2018;41(4):782–8.PubMedCrossRef
8.
Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117(8):1018–27.PubMedCrossRef
9.
10.
Abdelmalak B, Abdelmalak JB, Knittel J, Christiansen E, Mascha E, Zimmerman R, et al. The prevalence of undiagnosed diabetes in non-cardiac surgery patients, an observational study. Can J Anaesth. 2010;57(12):1058–64.PubMedCrossRef
11.
Cobas R, Rodacki M, Giacaglia L, Calliari LEP, Noronha RM, Valerio C, et al. Diagnóstico do diabetes e rastreamento do diabetes tipo 2. Diretriz oficial da sociedade brasileira de diabetes. Conectando Pessoas; 2022.
12.
Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–82.PubMedCrossRef
13.
Greci LS, Kailasam M, Malkani S, Katz DL, Hulinsky I, Ahmadi R, et al. Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care. 2003;26(4):1064–8.PubMedCrossRef
14.
Pasquel FJ, Gomez-Huelgas R, Anzola I, Oyedokun F, Haw JS, Vellanki P, et al. Predictive value of admission hemoglobin a1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care. 2015;38(12):e202–3.PubMedPubMedCentralCrossRef
15.
16.
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using hba1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40(8):994–9.PubMedPubMedCentralCrossRef
17.
Gounden V, Ngu M, Anastasopoulou C, Jialal I. Fructosamine. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
18.
Toyoshima MTK, Cukier P, Damascena AS, Batista RL, de Azevedo CF, Zanatta Kawahara E, et al. Fructosamine and glycated hemoglobin as biomarkers of glycemic control in people with type 2 diabetes mellitus and cancer (GlicoOnco study). Clinics. 2023;78:100240.PubMedPubMedCentralCrossRef
19.
Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003;26(1):163–7.PubMedCrossRef
20.
Vellanki P, Bean R, Oyedokun FA, Pasquel FJ, Smiley D, Farrokhi F, et al. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38(4):568–74.PubMedPubMedCentralCrossRef
21.
Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33.PubMedCrossRef
22.
Pérez-Belmonte LM, Gómez-Doblas JJ, Millán-Gómez M, López-Carmona MD, Guijarro-Merino R, Carrasco-Chinchilla F, et al. Use of linagliptin for the management of medicine department inpatients with type 2 diabetes in Real-World Clinical Practice (Lina-Real-World Study). J Clin Med. 2018;7(9):271.PubMedPubMedCentralCrossRef
23.
Ribeiro RS, Peres RB, Yamamoto MT, Novaes AP, Laselva CR, Faulhaber ACL, et al. Impact of screening and monitoring of capillary blood glucose in the detection of hyperglycemia and hypoglycemia in non-critical inpatients. Einstein. 2011;9(1):14–7.PubMedCrossRef
24.
25.
Arora S, Henderson SO, Long T, Menchine M. Diagnostic accuracy of point-of-care testing for diabetic ketoacidosis at emergency-department triage: {beta}-hydroxybutyrate versus the urine dipstick. Diabetes Care. 2011;34(4):852–4.PubMedPubMedCentralCrossRef
26.
Brooke J, Stiell M, Ojo O. Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review. Int J Environ Res Public Health. 2016;13(9):837.PubMedPubMedCentralCrossRef
27.
Santomauro AT, Santomauro Junior AC, Raduan RA, Bertoluci M. Diagnóstico e tratamento da cetoacidose diabética euglicêmica. Diretriz oficial da sociedade brasileira de diabetes. Conectando Pessoas; 2022.
28.
Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173(6):417–25.PubMedCrossRef
29.
Toyoshima MTK, Cukier P, Souza ABC de, Pereira J, Hoff AO, Nery M. Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study. Einstein. 2022;20:eAO8031.
30.
Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12(4):358–62.PubMedCrossRef
31.
Le VT, Ha QH, Tran MT, Le NT, Le VT, Le MK. Hyperglycemia in severe and critical COVID-19 patients: risk factors and outcomes. Cureus. 2022;14(8):e27611.PubMedPubMedCentral
32.
Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.PubMedCrossRef
33.
NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY-S, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97.
34.
Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American association of clinical endocrinologists and American diabetes association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.PubMedPubMedCentralCrossRef
35.
Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA. 2019;322(4):326–35.PubMedPubMedCentralCrossRef
36.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 16. Diabetes care in the hospital: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S267–78.
37.
Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169–74.PubMedPubMedCentralCrossRef
38.
Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38(12):2211–6.PubMedPubMedCentralCrossRef
39.
Drincic AT, Knezevich JT, Akkireddy P. Nutrition and hyperglycemia management in the inpatient setting (meals on demand, parenteral, or enteral nutrition). Curr Diab Rep. 2017;17(8):59.PubMedCrossRef
40.
Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, Low Wang CC. Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: a systematic review. Endocr Pract. 2022;28(11):1166–77.PubMedPubMedCentralCrossRef
41.
Khowaja A, Alkhaddo JB, Rana Z, Fish L. Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine hagedorn insulin protocol: a randomized clinical trial. Diabetes Ther. 2018;9(4):1647–55.PubMedPubMedCentralCrossRef
42.
Grommesh B, Lausch MJ, Vannelli AJ, Mullen DM, Bergenstal RM, Richter SA, et al. Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia. Endocr Pract. 2016;22(2):180–9.PubMedCrossRef
43.
44.
Alessi J, de Oliveira GB, Schaan BD, Telo GH. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020;12:80.PubMedPubMedCentralCrossRef
45.
Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021;10(10):2154.PubMedPubMedCentralCrossRef
46.
Magaji V, Johnston JM. Inpatient management of hyperglycemia and diabetes. Clin Diabetes. 2011;29(1):3–9.CrossRef
47.
Pasquel FJ, Lansang MC, Khowaja A, Urrutia MA, Cardona S, Albury B, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: glargine U300 hospital trial. Diabetes Care. 2020;43(6):1242–8.PubMedPubMedCentralCrossRef
48.
Galindo RJ, Pasquel FJ, Vellanki P, Alicic R, Lam DW, Fayfman M, et al. Degludec hospital trial: a randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes. Diabetes Obes Metab. 2022;24(1):42–9.PubMedCrossRef
49.
Zhang X, Zhang T, Xiang G, Wang W, Li Y, Du T, et al. Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study. BMJ Open Diabetes Res Care. 2020;8(1):e001261.PubMedPubMedCentralCrossRef
50.
Li X, Du T, Li W, Zhang T, Liu H, Xiong Y. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study. Clin Ther. 2014;36(9):1269–75.PubMedCrossRef
51.
Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(2):564–9.PubMedCrossRef
52.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–6.
53.
Trence DL, Kelly JL, Hirsch IB. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab. 2003;88(6):2430–7.PubMedCrossRef
54.
Rajendran R, Kerry C, Rayman G, MaGIC study group. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open. 2014;4(7):e005165.
55.
Bano T, Mishra SK, Kuchay MS, Mehta Y, Trehan N, Sharma P, et al. Continuation of metformin till night before surgery and lactate levels in patients undergoing coronary artery bypass graft surgery. Indian J Endocrinol Metab. 2019;23(4):416–21.PubMedPubMedCentralCrossRef
56.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967.
57.
Ma Z, Krishnamurthy M. Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? A multivariable and propensity score-adjusted meta-analysis. PLoS ONE. 2023;18(2):e0282210.PubMedPubMedCentralCrossRef
58.
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. Diabetes Obes Metab. 2019;21(4):837–43.PubMedCrossRef
59.
Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.PubMedPubMedCentralCrossRef
60.
Gracia-Ramos AE, Cruz-Dominguez MDP, Madrigal-Santillán EO, Rojas-Martínez R, Morales-González JA, Morales-González Á, et al. Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial. J Diabetes Complicat. 2024;38(5):108742.CrossRef
61.
Rabizadeh S, Tavakoli Ardakani MA, Mouodi M, Bitaraf M, Shab-Bidar S, Esteghamati A, et al. DPP4 inhibitors in the management of hospitalized patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Adv Ther. 2020;37(9):3660–75.PubMedCrossRef
62.
Daza-Arnedo R, Rico-Fontalvo J-E, Pájaro-Galvis N, Leal-Martínez V, Abuabara-Franco E, Raad-Sarabia M, et al. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review. Kidney Med. 2021;3(6):1065–73.PubMedPubMedCentralCrossRef
63.
Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of continued use of SGLT2 inhibitors from the ambulatory to inpatient setting with hospital outcomes in patients with diabetes: a nationwide cohort study. Diabetes Care. 2024;47(6):933–40.PubMedCrossRef
64.
Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018;20(1):25–33.PubMedCrossRef
65.
Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27–36.PubMedCrossRef
66.
Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A, et al. Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports. J Anesth. 2023;37(3):465–73.PubMedPubMedCentralCrossRef
67.
Umapathysivam MM, Morgan B, Inglis JM, Meyer E, Liew D, Thiruvenkatarajan V, et al. SGLT2 inhibitor-associated ketoacidosis vs type 1 diabetes-associated ketoacidosis. JAMA Netw Open. 2024;7(3):e242744.PubMedPubMedCentralCrossRef
68.
Sebastian-Valles F, Tapia-Sanchiz MS, Navas-Moreno V, Lopez-Ruano M, Martínez-Otero C, Carrillo-López E, et al. Chronic treatment with SGLT-2 inhibitors is associated with ICU admission and disease severity in patients with diabetic ketoacidosis: a propensity score-matched cohort study. Intern Emerg Med. 2024.
69.
Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586–94.PubMedPubMedCentralCrossRef
70.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–74.PubMedPubMedCentralCrossRef
71.
Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44(1):41–50.PubMedCrossRef
72.
Okoroike H, Patel S, Simone P, Lavelle R, Szwak JA. Impact of inpatient initiation of sodium-glucose cotransporter-2 inhibitors on prescription rates in patients with heart failure with reduced ejection fraction. Am J Cardiol. 2023;186:150–5.PubMedCrossRef
73.
Chieng JHL, Sia TK, Teo YH, Wong JZA, Ng TJY, Teo YN, et al. Evaluating the initiation of sodium/glucose cotransporter 2 inhibitors within 2 weeks of an acute hospital admission: a systematic review and meta-analysis of nine clinical trials. Med Princ Pract. 2022;31(3):215–23.PubMedPubMedCentralCrossRef
74.
Huang W, Whitelaw J, Kishore K, Neto AS, Holmes NE, Marhoon N, et al. The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors. J Diabetes Complicat. 2021;35(12):108052.CrossRef
75.
Watkins AR, Fialka N, El-Andari R, Kang JJ, Bozso SJ, Nagendran J. Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials. Future Cardiol. 2023;19:105–15.PubMedCrossRef
76.
Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091.
77.
Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. J Diabetes Investig. 2023;14(6):767–73.PubMedPubMedCentralCrossRef
78.
Sherwin M, Hamburger J, Katz D, DeMaria S. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023;70(8):1300–6.PubMedCrossRef
79.
Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43(5):430–7.PubMedCrossRef
80.
Yao R, Gala KS, Ghusn W, Abboud DM, Wallace FK, Vargas EJ. Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy. Am J Gastroenterol. 2024;119(6):1154–7.PubMedCrossRef
81.
Lansang MC, Modic MB, Sauvey R, Lock P, Ross D, Combs P, et al. Approach to the adult hospitalized patient on an insulin pump. J Hosp Med. 2013;8(12):721–7.PubMedCrossRef
82.
Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, et al. Continuous glucose monitoring: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(10):2968–79.PubMedCrossRef
83.
Clubbs Coldron B, Coates V, Khamis A, MacRury S. Use of continuous glucose monitoring in non-ICU hospital settings for people with diabetes: a scoping review of emerging benefits and issues. J Diabetes Sci Technol. 2023;17(2):467–73.PubMedCrossRef
84.
Voglová Hagerf B, Protus M, Nemetova L, Mraz M, Kieslichova E, Uchytilova E, et al. Accuracy and feasibility of real-time continuous glucose monitoring in critically Ill patients after abdominal surgery and solid organ transplantation. Diabetes Care. 2024;47(6):956–63.PubMedPubMedCentralCrossRef
85.
Klonoff DC, Kerr D. A Simplified approach using rate of change arrows to adjust insulin with real-time continuous glucose monitoring. J Diabetes Sci Technol. 2017;11(6):1063–9.PubMedPubMedCentralCrossRef
86.
Logtenberg SJ, Kleefstra N, Snellen FT, Groenier KH, Slingerland RJ, Nierich AP, et al. Pre- and postoperative accuracy and safety of a real-time continuous glucose monitoring system in cardiac surgical patients: a randomized pilot study. Diabetes Technol Ther. 2009;11(1):31–7.PubMedCrossRef
87.
Matievich W, Kiaie N, Dunn TC. Safety and functional integrity of CGM sensors when used during radiologic procedures under high exposure conditions. J Diabetes Sci Technol. 2022;17:1634-1643.
88.
Davis GM, Spanakis EK, Migdal AL, Singh LG, Albury B, Urrutia MA, et al. Accuracy of Dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes. Diabetes Care. 2021;44(7):1641–6.PubMedPubMedCentralCrossRef
89.
Davis GM, Galindo RJ, Migdal AL, Umpierrez GE. Diabetes technology in the inpatient setting for management of hyperglycemia. Endocrinol Metab Clin North Am. 2020;49(1):79–93.PubMedPubMedCentralCrossRef
90.
Nassar AA, Partlow BJ, Boyle ME, Castro JC, Bourgeois PB, Cook CB. Outpatient-to-inpatient transition of insulin pump therapy: successes and continuing challenges. J Diabetes Sci Technol. 2010;4(4):863–72.PubMedPubMedCentralCrossRef
91.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S97–110.
92.
McTavish L, Corley B, Weatherall M, Wiltshire E, Krebs JD. Weight-based carbohydrate treatment of hypoglycaemia in people with type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial. Diabet Med. 2018;35(3):339–46.PubMedCrossRef
93.
Georgakopoulos K, Katsilambros N, Fragaki M, Poulopoulou Z, Kimbouris J, Sfikakis P, et al. Recovery from insulin-induced hypoglycemia after saccharose or glucose administration. Clin Physiol Biochem. 1990;8(5):267–72.PubMed
94.
McTavish L, Wiltshire E. Effective treatment of hypoglycemia in children with type 1 diabetes: a randomized controlled clinical trial. Pediatr Diabetes. 2011;12(4 Pt 2):381–7.PubMedCrossRef
95.
Namba M, Hanafusa T, Kono N, Tarui S. Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group. Diabetes Res Clin Pract. 1993;19(2):133–8.
Metadata
Title
Screening and management of hospital hyperglycemia in non-critical patients: a position statement from the Brazilian Diabetes Society (SBD)
Authors
Emerson Cestari Marino
Denise Momesso
Marcos Tadashi Kakitani Toyoshima
Maria Fernanda Ozorio de Almeida
Beatriz D. Schaan
Leandra Anália Freitas Negretto
Augusto Cezar Santomauro Junior
Priscilla Cukier
Paulo Roberto Rizzo Genestreti
Alina Coutinho Rodrigues Feitosa
Jorge Eduardo da Silva Soares Pinto
Rogerio Silicani Ribeiro
Rodrigo Nunes Lamounier
Ruy Lyra
Marcello Casaccia Bertoluci
Publication date
12-02-2025

Other articles of this Issue 1/2025

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses

Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity

Prediction of unfavorable outcome of acute decompensation of diabetes mellitus

Association between various blood glucose variability-related indicators during early ICU admission and 28-day mortality in non-diabetic patients with sepsis

Association between air pollution and cardiovascular disease risk in middle-aged and elderly individuals with diabetes: inflammatory lipid ratio accelerate this progression

The combined impact of BMI and ABSI on all-cause mortality among American adults with diabetes

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits